These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 16490525)

  • 41. Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization secondary to pathologic myopia-1-year results of a prospective series.
    Lam DS; Liu DT; Fan DS; Lai WW; So SF; Chan WM
    Eye (Lond); 2005 Aug; 19(8):834-40. PubMed ID: 15375364
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Photodynamic therapy with verteporfin in patients with age-related macular degeneration and juxtafoveal choroidal neovascularization.
    Frennesson CI
    Acta Ophthalmol Scand; 2004 Dec; 82(6):651-5. PubMed ID: 15606459
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunohistopathologic evaluation of choroidal neovascular membranes following verteporfin-photodynamic therapy.
    Grisanti S; Tatar O; Canbek S; Lafaut BA; Gelisken F; Inhoffen W; Szurman P; Aisenbrey S; Oficjalska-Mlynczak J; Bartz-Schmidt KU
    Am J Ophthalmol; 2004 May; 137(5):914-23. PubMed ID: 15126158
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Verteporfin and photosensitivity in diabetic].
    Asensio Sánchez VM; Corral Azor A; García Pascual A
    Arch Soc Esp Oftalmol; 2003 May; 78(5):277-9. PubMed ID: 12789632
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization.
    Spaide RF; Sorenson J; Maranan L
    Ophthalmology; 2003 Aug; 110(8):1517-25. PubMed ID: 12917166
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularisation secondary to pathological myopia.
    Gibson J
    Eye (Lond); 2005 Aug; 19(8):829-30. PubMed ID: 16086038
    [No Abstract]   [Full Text] [Related]  

  • 47. Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2.
    Renno RZ; Terada Y; Haddadin MJ; Michaud NA; Gragoudas ES; Miller JW
    Arch Ophthalmol; 2004 Jul; 122(7):1002-11. PubMed ID: 15249365
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results.
    Antoszyk AN; Tuomi L; Chung CY; Singh A;
    Am J Ophthalmol; 2008 May; 145(5):862-74. PubMed ID: 18321465
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Influence of verteporfin photodynamic therapy on inflammation in human choroidal neovascular membranes secondary to age-related macular degeneration.
    Tatar O; Adam A; Shinoda K; Yoeruek E; Szurman P; Bopp S; Eckardt C; Bartz-Schmidt KU; Grisanti S
    Retina; 2007; 27(6):713-23. PubMed ID: 17621180
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Using intravenous diphenhydramine to minimize back pain associated with photodynamic therapy with verteporfin.
    Tornambe PE
    Arch Ophthalmol; 2002 Jun; 120(6):872. PubMed ID: 12049608
    [No Abstract]   [Full Text] [Related]  

  • 51. Anaphylactoid reaction after verteporfin therapy.
    Doshi AB; Moshfeghi DM; Jack RL
    Am J Ophthalmol; 2005 Nov; 140(5):936-7. PubMed ID: 16310483
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bilateral punctal-canalicular stenosis following photodynamic therapy for choroidal neovascularization.
    Yim JF; Crofts KP
    Cutan Ocul Toxicol; 2011 Mar; 30(1):78-9. PubMed ID: 20950246
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Acute severe vision decrease immediately after photodynamic therapy.
    Beaumont P; Lim CS; Chang A; Kang K
    Arch Ophthalmol; 2004 Oct; 122(10):1546-7. PubMed ID: 15477472
    [No Abstract]   [Full Text] [Related]  

  • 54. Photodynamic therapy using verteporfin-induced minimal change nephrotic syndrome.
    Kang SW; Kang SJ; Kim HO; Nam ES; Lee JH; Koh HJ
    Am J Ophthalmol; 2002 Dec; 134(6):907-8. PubMed ID: 12470762
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Increased and persisted subretinal haemorrhage after photodynamic therapy for choroidal neovascularization secondary to angioid streaks.
    Shyong MP; Chen SJ; Lee FL; Tsao YP; Hsu WM
    Eye (Lond); 2006 Dec; 20(12):1420-2. PubMed ID: 16645630
    [No Abstract]   [Full Text] [Related]  

  • 56. Adverse reaction characterized by chest pain, shortness of breath, and syncope associated with verteporfin (visudyne).
    Cahill MT; Smith BT; Fekrat S
    Am J Ophthalmol; 2002 Aug; 134(2):281-2. PubMed ID: 12140044
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Photodynamic therapy.
    Kotoula MG; Tsironi EE; Karabatsas CH; Chatzoulis DZ
    Retina; 2005 Jan; 25(1):102-3. PubMed ID: 15655455
    [No Abstract]   [Full Text] [Related]  

  • 58. Neutrophil margination as a possible mechanism for verteporfin infusion-associated pain.
    Spaide RF; Maranan L
    Am J Ophthalmol; 2003 Apr; 135(4):549-50. PubMed ID: 12654380
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Verteporfin and myocardial infarction.
    Schattner A; Pollack A
    Ann Pharmacother; 2004 Feb; 38(2):352. PubMed ID: 14742780
    [No Abstract]   [Full Text] [Related]  

  • 60. Accidental pregnancy exposure to verteporfin: obstetrical and neonatal outcomes: a case report.
    Rodrigues M; Meira D; Batista S; Carrilho MM
    Aust N Z J Obstet Gynaecol; 2009 Apr; 49(2):236-7. PubMed ID: 19432621
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.